person · Reporting owner

JEFFS ROGER

Disclosed activity across 6 companies

Tapewire entity: 30518
SEC CIK: 0001231615

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALBIREO PHARMA, INC.ALBO · Entity 116015	Director	June 24, 2021	June 28, 2021
Axsome Therapeutics, Inc.AXSM · Entity 2469	Director	June 10, 2026	June 12, 2026
Liquidia CorpLQDA · Entity 1860	Director · Chief Executive Officer	October 09, 2026	October 13, 2026
SANGAMO THERAPEUTICS, INCSGMO · Entity 7038	Director	September 07, 2018	September 07, 2018
Sio Gene Therapies Inc.AXGT · Entity 130622	Director	April 15, 2019	April 18, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALBIREO PHARMA, INC.

Report date June 24, 2021 · Filed June 28, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.87 · Expires 2031-06-23	Direct	8,000	Reported balance After 2021-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-24 · Grant · Acquired 8,000 · Balance 8,000 F1: This option will vest and become exercisable in full on the earlier of (i) June 24, 2022 or (ii) the day prior to the issuer's 2022 annual meeting of stockholders, subject to the director's continued service on the issuer's board of directors on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option will vest and become exercisable in full on the earlier of (i) June 24, 2022 or (ii) the day prior to the issuer's 2022 annual meeting of stockholders, subject to the director's continued service on the issuer's board of directors on the vesting date.

Axsome Therapeutics, Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	58,367	Ending reported balance After 2026-06-11 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-06-10 · Sale · Disposed 286 · Balance 58,653 F1: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F2: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. Row 2 · 2026-06-11 · Sale · Disposed 286 · Balance 58,367 F1: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F2: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.

F2: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.

Liquidia Corp

Report date October 09, 2026 · Filed October 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,125,848	Last balance in matching sequence After 2026-10-12 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2026-10-09 · Exercise / conversion · Acquired 13,833 · Balance 1,144,259 F2: On January 11, 2024, the Reporting Person was granted 221,338 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2025 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 152,170 have vested as of the date of this Form 4. F1: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F3: Includes (i) 18,094 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 69,168 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 128,996 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4. Row 2 · 2026-10-09 · Exercise / conversion · Acquired 14,333 · Balance 1,158,592 F4: On January 11, 2025, the Reporting Person was granted 229,327 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2026 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 100,331 have vested as of the date of this Form 4. F1: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F3: Includes (i) 18,094 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 69,168 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 128,996 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4. Row 3 · 2026-10-12 · Sale · Disposed 32,744 · Balance 1,125,848 F5: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023. F6: These shares were sold to cover taxes associated with the settlement of RSUs and PSUs that were initially granted to the Reporting Person on January 11, 2023, January 11, 2024 and January 11, 2025. F3: Includes (i) 18,094 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 69,168 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 128,996 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	69,168	Reported balance After 2026-10-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-10-09 · Exercise / conversion · Disposed 13,833 · Balance 69,168 F1: Performance stock units ("PSUs") convert into common stock on a one-for-one basis.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	128,996	Reported balance After 2026-10-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-10-09 · Exercise / conversion · Disposed 14,333 · Balance 128,996 F1: Performance stock units ("PSUs") convert into common stock on a one-for-one basis.
Common StockSEC Table I · non-derivative	IndirectSee footnote	46,595	Reported balance Holding disclosure · report date 2026-10-09 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 46,595 F7: The securities are held by Roger A. Jeffs Living Trust UAD 2/29/2000 (the "Trust"). The Reporting Person is the trustee of the Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,041,667	Reported balance Holding disclosure · report date 2026-10-09 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 1,041,667 F8: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity.

Filing footnotes · ownership attribution and instrument terms

F1: Performance stock units ("PSUs") convert into common stock on a one-for-one basis.

F2: On January 11, 2024, the Reporting Person was granted 221,338 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2025 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 152,170 have vested as of the date of this Form 4.

F3: Includes (i) 18,094 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 69,168 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 128,996 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4.

F4: On January 11, 2025, the Reporting Person was granted 229,327 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2026 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 100,331 have vested as of the date of this Form 4.

F5: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.

F6: These shares were sold to cover taxes associated with the settlement of RSUs and PSUs that were initially granted to the Reporting Person on January 11, 2023, January 11, 2024 and January 11, 2025.

F7: The securities are held by Roger A. Jeffs Living Trust UAD 2/29/2000 (the "Trust"). The Reporting Person is the trustee of the Trust.

F8: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity.

SANGAMO THERAPEUTICS, INC

Report date September 07, 2018 · Filed September 07, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	9,908	Reported balance After 2018-09-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-09-07 · Purchase · Acquired 7,408 · Balance 9,908 F1: The price reported is a weighted average price. The shares were purchased at prices ranging from $13.475 to $13.60. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F2: Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 11, 2018. The RSUs will fully vest on the earlier of (x) June 11, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. The shares were purchased at prices ranging from $13.475 to $13.60. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F2: Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 11, 2018. The RSUs will fully vest on the earlier of (x) June 11, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

Sio Gene Therapies Inc.

Report date April 15, 2019 · Filed April 18, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2029-04-14	Direct	255,000	Reported balance After 2019-04-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-04-15 · Grant · Acquired 255,000 · Balance 255,000 F1: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Dova Pharmaceuticals Inc.

Report date November 12, 2019 · Filed November 12, 2019

Section 16 reporting ended · disclosed 2019-11-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-11-12 transaction · row 1 1 source row Row 1 · 2019-11-12 · Disposition to issuer · Disposed 66,993 · Balance 0 F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.32 · Expires 2027-05-24	Direct	Reported balance After 2019-11-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-12 · Disposition to issuer · Disposed 33,000 · Balance 0 F2: This option, which provided for vesting over a period of three years as follows: (i) one-third of the total shares subject to the option shall vest on May 25, 2018, and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $665,940.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.36 · Expires 2029-04-25	Direct	Reported balance After 2019-11-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.

F2: This option, which provided for vesting over a period of three years as follows: (i) one-third of the total shares subject to the option shall vest on May 25, 2018, and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $665,940.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.

F3: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 12, 2026 Filed Oct 13, 2026 23:59 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	32,744	$28.48	$932,549.12	Disclosure SEC source: 0001104659-26-115642 · tm2627530-3_4seq1.xml · nonDerivative · entry 3 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,125,848 F5 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023. F6 · shares: These shares were sold to cover taxes associated with the settlement of RSUs and PSUs that were initially granted to the Reporting Person on January 11, 2023, January 11, 2024 and January 11, 2025. F3 · balance_after: Includes (i) 18,094 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 69,168 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 128,996 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4. Read SEC document
October 09, 2026 Filed Oct 13, 2026 23:59 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionPerformance Stock Units · Derivative	14,333	$0.00	$0.00	Disclosure SEC source: 0001104659-26-115642 · tm2627530-3_4seq1.xml · derivative · entry 7 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,996 Underlying: Common Stock · 14,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.exercise_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.expiration_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. Read SEC document
October 09, 2026 Filed Oct 13, 2026 23:59 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionPerformance Stock Units · Derivative	13,833	$0.00	$0.00	Disclosure SEC source: 0001104659-26-115642 · tm2627530-3_4seq1.xml · derivative · entry 6 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,168 Underlying: Common Stock · 13,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.exercise_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.expiration_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. Read SEC document
October 09, 2026 Filed Oct 13, 2026 23:59 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionCommon Stock	14,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-26-115642 · tm2627530-3_4seq1.xml · nonDerivative · entry 2 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,158,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: On January 11, 2025, the Reporting Person was granted 229,327 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2026 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 100,331 have vested as of the date of this Form 4. F1 · price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F3 · balance_after: Includes (i) 18,094 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 69,168 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 128,996 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4. Read SEC document
October 09, 2026 Filed Oct 13, 2026 23:59 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionCommon Stock	13,833	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-26-115642 · tm2627530-3_4seq1.xml · nonDerivative · entry 1 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,144,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: On January 11, 2024, the Reporting Person was granted 221,338 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2025 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 152,170 have vested as of the date of this Form 4. F1 · price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F3 · balance_after: Includes (i) 18,094 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 69,168 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 128,996 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4. Read SEC document
July 13, 2026 Filed Jul 15, 2026 00:07 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	32,744	$71.52	$2,341,850.88	Disclosure SEC source: 0001104659-26-083619 · tm2620529-6_4seq1.xml · nonDerivative · entry 4 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,130,426 F5 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023. F6 · shares: These shares were sold to cover taxes associated with the settlement of RSUs and PSUs that were initially granted to the Reporting Person on January 11, 2023, January 11, 2024 and January 11, 2025. F3 · balance_after: Includes (i) 36,187 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 83,001 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 143,329 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4. Read SEC document
July 13, 2026 Filed Jul 15, 2026 00:07 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	2,505	$71.39	$178,831.95	Disclosure SEC source: 0001104659-26-083619 · tm2620529-6_4seq1.xml · nonDerivative · entry 3 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,163,170 F5 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023. F6 · shares: These shares were sold to cover taxes associated with the settlement of RSUs and PSUs that were initially granted to the Reporting Person on January 11, 2023, January 11, 2024 and January 11, 2025. F3 · balance_after: Includes (i) 36,187 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 83,001 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 143,329 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4. Read SEC document
July 10, 2026 Filed Jul 15, 2026 00:07 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionPerformance Stock Units · Derivative	14,333	$0.00	$0.00	Disclosure SEC source: 0001104659-26-083619 · tm2620529-6_4seq1.xml · derivative · entry 8 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,329 Underlying: Common Stock · 14,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.exercise_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.expiration_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. Read SEC document
July 10, 2026 Filed Jul 15, 2026 00:07 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionPerformance Stock Units · Derivative	13,834	$0.00	$0.00	Disclosure SEC source: 0001104659-26-083619 · tm2620529-6_4seq1.xml · derivative · entry 7 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,001 Underlying: Common Stock · 13,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.exercise_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.expiration_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. Read SEC document
July 10, 2026 Filed Jul 15, 2026 00:07 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionCommon Stock	14,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-26-083619 · tm2620529-6_4seq1.xml · nonDerivative · entry 2 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,165,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: On January 11, 2025, the Reporting Person was granted 229,327 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2026 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 85,998 have vested as of the date of this Form 4. F1 · price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F3 · balance_after: Includes (i) 36,187 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 83,001 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 143,329 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4. Read SEC document
July 10, 2026 Filed Jul 15, 2026 00:07 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionCommon Stock	13,834	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-26-083619 · tm2620529-6_4seq1.xml · nonDerivative · entry 1 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,151,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: On January 11, 2024, the Reporting Person was granted 221,338 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2025 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 138,337 have vested as of the date of this Form 4. F1 · price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F3 · balance_after: Includes (i) 36,187 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 83,001 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 143,329 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4. Read SEC document
June 11, 2026 Filed Jun 12, 2026 00:34 UTC	Axsome Therapeutics, Inc. AXSM · Entity 2469	SaleCommon Stock	286	$249.12	$71,248.32	Disclosure SEC source: 0001193125-26-268202 · ownership.xml · nonDerivative · entry 2 JEFFS ROGER · CIK 0001231615 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,367 F1 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F2 · shares: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. Read SEC document
June 10, 2026 Filed Jun 12, 2026 00:34 UTC	Axsome Therapeutics, Inc. AXSM · Entity 2469	SaleCommon Stock	286	$246.18	$70,407.48	Disclosure SEC source: 0001193125-26-268202 · ownership.xml · nonDerivative · entry 1 JEFFS ROGER · CIK 0001231615 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,653 F1 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F2 · shares: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. Read SEC document
June 08, 2026 Filed Jun 11, 2026 01:49 UTC	Axsome Therapeutics, Inc. AXSM · Entity 2469	Exercise / conversionRestricted Stock Units · Derivative	1,429	$0.00	$0.00	Disclosure SEC source: 0001193125-26-266437 · ownership.xml · derivative · entry 2 JEFFS ROGER · CIK 0001231615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · derivative.expiration_date: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document
June 08, 2026 Filed Jun 11, 2026 01:49 UTC	Axsome Therapeutics, Inc. AXSM · Entity 2469	Exercise / conversionCommon Stock	1,429	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-266437 · ownership.xml · nonDerivative · entry 1 JEFFS ROGER · CIK 0001231615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant. F2 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document
June 05, 2026 Filed Jun 9, 2026 21:15 UTC	Axsome Therapeutics, Inc. AXSM · Entity 2469	GrantRestricted Stock Units · Derivative	1,721	$0.00	$0.00	Disclosure SEC source: 0001193125-26-264030 · ownership.xml · derivative · entry 1 JEFFS ROGER · CIK 0001231615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,721 Underlying: Common Stock · 1,721 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest in full on the one-year anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vest in full on the one-year anniversary of the date of grant. Read SEC document
May 27, 2026 Filed May 28, 2026 20:30 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	6,428	$62.18	$399,712.32	Disclosure SEC source: 0001104659-26-067540 · tm2615888-1_4seq1.xml · nonDerivative · entry 3 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,041,667 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F4 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $59.99 to $63.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 26, 2026 Filed May 26, 2026 22:16 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$60.38	$1,509,460.00	Disclosure SEC source: 0001104659-26-066415 · tm2615686-1_4seq1.xml · nonDerivative · entry 5 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,048,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F7 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $59.16 to $62.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 22, 2026 Filed May 26, 2026 22:16 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$61.52	$1,538,055.00	Disclosure SEC source: 0001104659-26-066415 · tm2615686-1_4seq1.xml · nonDerivative · entry 4 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,073,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F6 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $60.79 to $62.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 21, 2026 Filed May 26, 2026 22:16 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$61.13	$1,528,160.00	Disclosure SEC source: 0001104659-26-066415 · tm2615686-1_4seq1.xml · nonDerivative · entry 3 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,098,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F4 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $60.03 to $62.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 20, 2026 Filed May 20, 2026 22:55 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$61.30	$1,532,547.50	Disclosure SEC source: 0001104659-26-064695 · tm2615261-1_4seq1.xml · nonDerivative · entry 5 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,123,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F7 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $59.96 to $62.17. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 19, 2026 Filed May 20, 2026 22:55 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$58.65	$1,466,142.50	Disclosure SEC source: 0001104659-26-064695 · tm2615261-1_4seq1.xml · nonDerivative · entry 4 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,148,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F6 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $56.15 to $60.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 18, 2026 Filed May 20, 2026 22:55 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$56.77	$1,419,320.00	Disclosure SEC source: 0001104659-26-064695 · tm2615261-1_4seq1.xml · nonDerivative · entry 3 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,173,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F4 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $56.02 to $58.05. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 15, 2026 Filed May 15, 2026 22:59 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$57.04	$1,426,072.50	Disclosure SEC source: 0001104659-26-062852 · tm2614860-1_4seq1.xml · nonDerivative · entry 5 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,198,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F7 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $56.18 to $58.60. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 14, 2026 Filed May 15, 2026 22:59 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$58.62	$1,465,565.00	Disclosure SEC source: 0001104659-26-062852 · tm2614860-1_4seq1.xml · nonDerivative · entry 4 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,223,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F6 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $56.47 to $59.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 13, 2026 Filed May 15, 2026 22:59 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$56.29	$1,407,127.50	Disclosure SEC source: 0001104659-26-062852 · tm2614860-1_4seq1.xml · nonDerivative · entry 3 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,248,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F4 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $53.99 to $57.77. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 12, 2026 Filed May 12, 2026 22:52 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$54.04	$1,350,990.00	Disclosure SEC source: 0001104659-26-059578 · tm2614438-1_4seq1.xml · nonDerivative · entry 5 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,273,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F7 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $50.68 to $56.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 11, 2026 Filed May 12, 2026 22:52 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$41.50	$1,037,402.50	Disclosure SEC source: 0001104659-26-059578 · tm2614438-1_4seq1.xml · nonDerivative · entry 4 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,298,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F6 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $40.05 to $44.09. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 08, 2026 Filed May 12, 2026 22:52 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$42.14	$1,053,565.00	Disclosure SEC source: 0001104659-26-059578 · tm2614438-1_4seq1.xml · nonDerivative · entry 3 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,323,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F4 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $41.08 to $42.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 07, 2026 Filed May 7, 2026 22:19 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$42.09	$1,052,135.00	Disclosure SEC source: 0001104659-26-057339 · tm2613988-1_4seq1.xml · nonDerivative · entry 5 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,348,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F7 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $41.05 to $42.87. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 06, 2026 Filed May 7, 2026 22:19 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$40.78	$1,019,572.50	Disclosure SEC source: 0001104659-26-057339 · tm2613988-1_4seq1.xml · nonDerivative · entry 4 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,373,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F6 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $40.09 to $41.19. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
May 05, 2026 Filed May 7, 2026 22:19 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$40.10	$1,002,592.50	Disclosure SEC source: 0001104659-26-057339 · tm2613988-1_4seq1.xml · nonDerivative · entry 3 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,398,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F4 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $40.00 to $40.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
April 17, 2026 Filed Apr 21, 2026 20:30 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	18,839	$40.60	$764,955.71	Disclosure SEC source: 0001104659-26-046046 · tm2612297-1_4seq1.xml · nonDerivative · entry 3 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,423,095 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F4 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $40.00 to $41.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
April 16, 2026 Filed Apr 17, 2026 00:38 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$40.31	$1,007,800.00	Disclosure SEC source: 0001104659-26-044512 · tm2612047-2_4seq1.xml · nonDerivative · entry 5 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,441,934 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F6 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $40.00 to $40.72. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
April 15, 2026 Filed Apr 17, 2026 00:38 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$40.14	$1,003,522.50	Disclosure SEC source: 0001104659-26-044512 · tm2612047-2_4seq1.xml · nonDerivative · entry 4 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,466,934 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F5 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $40.00 to $40.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
April 14, 2026 Filed Apr 17, 2026 00:38 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	3,300	$40.00	$132,000.00	Disclosure SEC source: 0001104659-26-044512 · tm2612047-2_4seq1.xml · nonDerivative · entry 3 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,491,934 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F4 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
April 13, 2026 Filed Apr 14, 2026 21:05 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	32,744	$38.37	$1,256,387.28	Disclosure SEC source: 0001104659-26-043262 · tm2611789-1_4seq1.xml · nonDerivative · entry 3 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,137,599 F5 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023. F6 · shares: These shares were sold to cover taxes associated with the settlement of RSUs and PSUs that were initially granted to the Reporting Person on January 11, 2023, January 11, 2024 and January 11, 2025. F3 · balance_after: Includes (i) 54,281 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 96,835 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 157,662 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4. Read SEC document
April 10, 2026 Filed Apr 14, 2026 21:05 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionPerformance Stock Units · Derivative	14,333	$0.00	$0.00	Disclosure SEC source: 0001104659-26-043262 · tm2611789-1_4seq1.xml · derivative · entry 7 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,662 Underlying: Common Stock · 14,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.exercise_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.expiration_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. Read SEC document
April 10, 2026 Filed Apr 14, 2026 21:05 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionPerformance Stock Units · Derivative	13,834	$0.00	$0.00	Disclosure SEC source: 0001104659-26-043262 · tm2611789-1_4seq1.xml · derivative · entry 6 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,835 Underlying: Common Stock · 13,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.exercise_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.expiration_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. Read SEC document
April 10, 2026 Filed Apr 14, 2026 21:05 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	21,433	$40.12	$859,876.96	Disclosure SEC source: 0001104659-26-043262 · tm2611789-1_4seq1.xml · nonDerivative · entry 5 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,495,234 F8 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F9 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $40.00 to $40.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
April 10, 2026 Filed Apr 14, 2026 21:05 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionCommon Stock	14,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-26-043262 · tm2611789-1_4seq1.xml · nonDerivative · entry 2 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,170,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: On January 11, 2025, the Reporting Person was granted 229,327 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2026 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 71,665 have vested as of the date of this Form 4. F1 · price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F3 · balance_after: Includes (i) 54,281 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 96,835 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 157,662 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4. Read SEC document
April 10, 2026 Filed Apr 14, 2026 21:05 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionCommon Stock	13,834	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-26-043262 · tm2611789-1_4seq1.xml · nonDerivative · entry 1 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,156,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: On January 11, 2024, the Reporting Person was granted 221,338 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2025 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 124,503 have vested as of the date of this Form 4. F1 · price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F3 · balance_after: Includes (i) 54,281 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 96,835 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 157,662 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4. Read SEC document
April 09, 2026 Filed Apr 13, 2026 21:47 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	25,000	$40.12	$1,002,887.50	Disclosure SEC source: 0001104659-26-042711 · tm2611705-2_4seq1.xml · nonDerivative · entry 3 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,516,667 F3 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. F4 · price: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $40.00 to $40.33. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document
January 16, 2026 Filed Jan 21, 2026 23:24 UTC	Liquidia Corp LQDA · Entity 1860	GrantPerformance Stock Units · Derivative	173,016	$0.00	$0.00	Disclosure SEC source: 0001104659-26-005485 · tm263781-7_4seq1.xml · derivative · entry 4 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,016 Underlying: Common Stock · 173,016 shares Expires not disclosed F4 · derivative.exercise_price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On January 16, 2026, the Reporting Person was granted 173,016 PSUs which vest upon the following time-based vesting schedule: (i) 25% of the PSUs shall vest on the Initial Vesting Date or, if later, the date on which the Issuer files its Form 10-K for the fiscal year ending December 31, 2026 (the "FY2026 10-K") and (ii) 6.25% of the PSUs vesting every three months following the Initial Vesting Date; so long as it satisfies the milestone-based vesting condition: the applicable percentage of the RSUs vesting based on net product sales revenue from YUTREPIA in 2026 as disclosed in the Issuer's FY2026 10-K. F5 · derivative.expiration_date: On January 16, 2026, the Reporting Person was granted 173,016 PSUs which vest upon the following time-based vesting schedule: (i) 25% of the PSUs shall vest on the Initial Vesting Date or, if later, the date on which the Issuer files its Form 10-K for the fiscal year ending December 31, 2026 (the "FY2026 10-K") and (ii) 6.25% of the PSUs vesting every three months following the Initial Vesting Date; so long as it satisfies the milestone-based vesting condition: the applicable percentage of the RSUs vesting based on net product sales revenue from YUTREPIA in 2026 as disclosed in the Issuer's FY2026 10-K. Read SEC document
January 16, 2026 Filed Jan 21, 2026 23:24 UTC	Liquidia Corp LQDA · Entity 1860	GrantCommon Stock	115,344	$0.00	$0.00	Disclosure SEC source: 0001104659-26-005485 · tm263781-7_4seq1.xml · nonDerivative · entry 1 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,152,872 F1 · kind: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · shares: (i) 25% of the RSUs shall vest on January 11, 2027 (the "Initial Vesting Date") and (ii) 6.25% of the RSUs vesting every three months following the Initial Vesting Date. F3 · balance_after: Includes (i) 72,375 unvested RSUs of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 110,669 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 171,995 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025, (iv) 115,344 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4 and (v) 10,696 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Read SEC document
January 12, 2026 Filed Jan 13, 2026 21:33 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	66,610	$37.43	$2,493,212.30	Disclosure SEC source: 0001104659-26-003367 · tm263060-3_4seq1.xml · nonDerivative · entry 3 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,037,528 F5 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023. F6 · shares: These shares were sold to cover taxes associated with the settlement of RSUs and PSUs that were initially granted to the Reporting Person on January 11, 2023, January 11, 2024 and January 11, 2025. F3 · balance_after: Includes (i) 72,375 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 110,669 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 171,995 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 10,696 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:33 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionPerformance Stock Units · Derivative	57,332	$0.00	$0.00	Disclosure SEC source: 0001104659-26-003367 · tm263060-3_4seq1.xml · derivative · entry 7 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,995 Underlying: Common Stock · 57,332 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.exercise_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.expiration_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:33 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionPerformance Stock Units · Derivative	13,833	$0.00	$0.00	Disclosure SEC source: 0001104659-26-003367 · tm263060-3_4seq1.xml · derivative · entry 6 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,669 Underlying: Common Stock · 13,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.exercise_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F1 · derivative.expiration_date: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:33 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionCommon Stock	57,332	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-26-003367 · tm263060-3_4seq1.xml · nonDerivative · entry 2 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,104,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: On January 11, 2025, the Reporting Person was granted 229,327 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2026 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 57,332 have vested as of the date of this Form 4. F1 · price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F3 · balance_after: Includes (i) 72,375 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 110,669 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 171,995 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 10,696 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:33 UTC	Liquidia Corp LQDA · Entity 1860	Exercise / conversionCommon Stock	13,833	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-26-003367 · tm263060-3_4seq1.xml · nonDerivative · entry 1 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,046,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: On January 11, 2024, the Reporting Person was granted 221,338 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2025 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 110,669 have vested as of the date of this Form 4. F1 · price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F3 · balance_after: Includes (i) 72,375 unvested restricted stock units ("RSUs") of the 289,500 RSUs granted to the Reporting Person on January 11, 2023, (ii) 110,669 unvested RSUs of the 221,338 RSUs granted to the Reporting Person on January 11, 2024, (iii) 171,995 unvested RSUs of the 229,327 RSUs granted to the Reporting Person on January 11, 2025 and (iv) 10,696 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.